Current asthma management – Best practice in 2023
GINA guidelines recommend as-needed budesonide/formoterol as the only treatment for the majority of patients with mild asthma at steps 1 and 2
Learning objectives
- An understanding of which patients are at risk of severe asthma exacerbations
- An awareness of the dangers associated with the regular use and overuse of short-acting β-agonist reliever therapy
- Familiarity with the clinical evidence of benefit when using the single maintenance and reliever therapy (SMART) approach for the management of asthma
- An awareness of current biologic therapies for the treatment of severe asthma.
Webinar held on 10 August 2023
ATTENTIONKindly note that if you attended the live webinar, you have already received 1 CPD point and will not be permitted to receive additional points for the report. Should this occur, the HPCSA will only record 1 CPD point from the live webinar, invalidating any additional CPD points from the report. Please note deNovo Medica ensures uploading of your CPD points to the HPCSA: please don't upload these yourself.
To access this module, please register or login: